Qdenga (dengue tetravalent vaccine (live, attenuated))
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- dengue tetravalent vaccine (live, attenuated)
- Company
- Takeda Pharmaceuticals International AG Ireland Branch
- Status
- Authorised
- Therapeutic area
- Dengue
- CHMP opinion
- Thu 13 Oct 2022
- EU approval
- Mon 05 Dec 2022
- Designations
- Additional monitoring
- Application
- EMEA/H/C/005155
- ATC
- J07BX04
- Official record
- www.ema.europa.eu
Indication
Qdenga is indicated for the prevention of dengue disease in individuals from 4 years of age. The use of Qdenga should be in accordance with official recommendations.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Dengvaxia Withdrawn · Sanofi Winthrop Industrie
Follow Qdenga
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.